Cervical Cancer clinical trials in Louisiana

11 actively recruiting cervical cancer trials at 6 sites across Louisiana.

Data from ClinicalTrials.gov · last refreshed 2026-09-07

Phase 3 Recruiting NIH

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment o…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT07061977

Sites in Louisiana:

West Jefferson Medical Center — Marrero, Louisiana
East Jefferson General Hospital — Metairie, Louisiana
LSU Healthcare Network / Metairie Multi-Specialty Clinic — Metairie, Louisiana
University Medical Center New Orleans — New Orleans, Louisiana
Ochsner Baptist Medical Center — New Orleans, Louisiana

View on ClinicalTrials.gov →

Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology

NCT ID: NCT04333537

Sites in Louisiana:

LSU Health Sciences Center at Shreveport — Shreveport, Louisiana

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Sponsor: Merus B.V.

NCT ID: NCT06525220

Sites in Louisiana:

Site 162 — Baton Rouge, Louisiana

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body. Researchers want to …

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT07216703

Sites in Louisiana:

TRIALS 365 ( Site 6008) — Shreveport, Louisiana

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…

Sponsor: ECOG-ACRIN Cancer Research Group

NCT ID: NCT02734537

Sites in Louisiana:

Louisiana State University Health Science Center — New Orleans, Louisiana
University Medical Center New Orleans — New Orleans, Louisiana
Touro Infirmary — New Orleans, Louisiana

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.

NCT ID: NCT03093116

Sites in Louisiana:

Local Institution - 2116 — New Orleans, Louisiana

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemip…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06980038

Sites in Louisiana:

Ochsner Medical Center Jefferson — New Orleans, Louisiana

View on ClinicalTrials.gov →

Phase 4 Recruiting Industry

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them fro…

Sponsor: Pfizer

NCT ID: NCT06952660

Sites in Louisiana:

University Medical Center - New Orleans — New Orleans, Louisiana
Trials365, LLC — Shreveport, Louisiana
Willis Knighton Cancer Center — Shreveport, Louisiana
Willis Knighton Physician Network - Hematology/Oncology — Shreveport, Louisiana
Willis Knighton Physician Network/Gynecologic Oncology Associates — Shreveport, Louisiana

View on ClinicalTrials.gov →

Recruiting Academic/Other

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus…

Sponsor: Mayo Clinic

NCT ID: NCT05051722

Sites in Louisiana:

Ochsner Clinic Foundation — New Orleans, Louisiana

View on ClinicalTrials.gov →

NA Recruiting NIH

Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04)

This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention. HPV is a comm…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT07281430

Sites in Louisiana:

Louisiana State University — Lafayette, Louisiana
Louisiana State University Health Science Center — New Orleans, Louisiana

View on ClinicalTrials.gov →

Phase 4 Recruiting Academic/Other

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV

The primary objective of this study is to determine the magnitude and breadth of the serum antibody response to the nonavalent HPV vaccine (Gardasil-9) in adults with well-controlled HIV infection. The secondary objectives of the study are…

Sponsor: Louisiana State University Health Sciences Center in New Orleans

NCT ID: NCT05266898

Sites in Louisiana:

University Medical Center New Orleans — New Orleans, Louisiana

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07